Haverford Trust CO Lineage Cell Therapeutics, Inc. Call Options Transaction History

Haverford Trust CO

  • $10.2 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $102M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Haverford Trust CO Portfolio

Follow Haverford Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Haverford Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Haverford Trust CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email